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Highlights 1 
<   Proof of a novel signaling modality mediating inter-population crosstalk in the brain 2 
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 4 
 Dendritic VP release from neurosecretory neurons stimulates autonomic neurons 5 
 Crosstalk involves Ca2+-mediated activation of a CAN channel in autonomic neurons 6 
 This crosstalk is involved in the generation of polymodal homeostatic responses  7 
!8 
!9 
10 
 3 
SUMMARY  1 
While communication between neurons is classically considered a function of the 2 
synapse, neurons can also release neurotransmitter from their dendrites.  We found that 3 
dendritic transmitter release coordinates activity across distinct neuronal populations to 4 
generate integrative homeostatic physiological responses. We show that activity-5 
dependent release of vasopressin from hypothalamic neuroendocrine neurons in the 6 
paraventricular nucleus stimulates neighboring (~100 µm soma-to-soma) 7 
presympathetic neurons, resulting in a sympathoexcitatory population response. This 8 
inter-population crosstalk was engaged by an NMDA-mediated increase in dendritic 9 
Ca2+8#4 +/(-6'/%'&$:7#4013'44+/A4#$+-+5: 50&+((64' +/ 5*''953#%'--6-#341#%e, and 10 
involved activation of CAN channels at the target neurons. Furthermore, we 11 
demonstrate that this inter-population crosstalk plays a pivotal role in the generation of a 12 
systemic, polymodal neurohumoral homeostatic response to a hyperosmotic challenge. 13 
Since dendritic release is emerging as a widespread process, our results suggest that a 14 
similar mechanism could mediate inter-population crosstalk in other brain systems, 15 
particularly those involved in generating complex behaviors. 16 
17 
 4 
INTRODUCTION  1 
Information processing in the CNS involves a wide array of spatiotemporal scales, 2 
ranging from temporally fast and spatially precise (critical for coherent spike timing 3 
between two neurons (Galarreta and Hestrin, 2001), to temporally slow and spatially 4 
diffuse, a modality best-suited for the coordination of activity within or across entire 5 
neuronal populations (Fuxe et al., 2007; Leng and Ludwig, 2008). Despite the 6 
importance of the latter in the generation of complex behaviors (Ludwig and Leng, 7 
2006), the precise signaling mechanisms underlying inter-population crosstalk in the 8 
brain remain largely unknown.  9 
Neuropeptides are increasingly recognized as unique signals involved in information 10 
processing in the brain (Leng and Ludwig, 2008; Salio et al., 2006). They are 11 
abundantly found in dendrites (Guan et al., 2005; Pow and Morris, 1989), their release 12 
is generally not confined to, or targeted at synaptic/postsynaptic sites, and given their 13 
relatively long half-lives (Mens et al., 1983), they can diffuse in the extracellular space 14 
(ECS) to act on distant targets. Thus, unlike classical fast-acting neurotransmitters, 15 
neuropeptide signaling lacks temporal and spatial precision, making it ideally suited to 16 
mediate communication between populations of neurons (Fuxe et al., 2007; Landgraf 17 
and Neumann, 2004; Ludwig and Leng, 2006).   18 
Neuropeptides are widely used as signaling molecules in the hypothalamus, 19 
particularly within the supraoptic (SON) and paraventricular (PVN) nuclei. These centers 20 
are critically involved in the generation of complex polymodal homeostatic responses, 21 
consisting of orchestrated activities of autonomic and neuroendocrine networks (Buijs 22 
and Van Eden, 2000; Swanson and Sawchenko, 1980). During disturbances of 23 
fluid/electrolyte homeostasis, activation of magnocellular neurosecretory (MNNs) and 24 
presympathetic neurons in the PVN results in the concerted systemic release of the 25 
hormone vasopressin (VP), along with an increase in renal sympathetic outflow, 26 
respectively, acting together to restore fluid/electrolyte balance (Bourque, 2008; Toney 27 
and Stocker, 2010). Importantly, an imbalanced interaction amongst these systems 28 
results in maladaptive responses characteristic of disease conditions, including stress, 29 
and hypertension (Ely, 1995; Esler et al., 1995). Thus, generation of homeostatic 30 
 5 
responses by the PVN represents an ideal paradigm to study inter-population signaling 1 
mechanisms within the brain, both under physiological and pathological conditions. 2 
In addition to playing key roles in the processing and integration of synaptic inputs, 3 
dendrites are recognized to be major sources of brain neuropeptides (Guan et al., 2005; 4 
Pow and Morris, 1989), MNNs being one of the best-studied prototypes of dendritic 5 
peptide release (Ludwig and Leng, 2006). Besides releasing their peptide content from 6 
neurohypophyseal axonal terminals into the circulation, MNNs also release VP and 7 
oxytocin (OT) locally from their dendrites, serving as a powerful autocrine signal by 8 
which they auto-regulate their activity (Gouzenes et al., 1998; Ludwig and Leng, 1997). 9 
However, whether dendritically released peptides from MNNs can act beyond their own 10 
secreting population, to mediate inter-population crosstalk, has not yet being explored. 11 
Using the magnocellular neurosecretory system as a unique model system, we tested 12 
the hypothesis that dendritic peptide release constitutes a powerful inter-population 13 
signaling modality in the brain. More specifically, we assessed whether dendritically 14 
released VP mediates crosstalk between neurosecretory and presympathetic 15 
hypothalamic neurons in the context of homeostatic neurohumoral responses to an 16 
osmotic challenge.  17 
Using a combination of in vitro approaches in acute hypothalamic slices, including 18 
patch-clamp electrophysiology, confocal imaging and laser photolysis of caged 19 
molecules, we demonstrate that dendritically-released VP from a single stimulated 20 
neurosecretory neuron evoked a direct excitatory response in presympathetic neurons 21 
located ~100 µm away. Moreover, we found that activity-dependent dendritic VP 22 
release from the whole population of neurosecretory neurons translated into a diffusible 23 
pool of peptide that tonically stimulated presympathetic neuronal activity. Finally, using 24 
an in vivo homeostatic challenge, we show that dendritic VP release is critical for the 25 
recruitment of presympathetic neurons, resulting in an optimal sympathoexcitatory 26 
outflow during a homeostatic challenge that requires an orchestrated neurosecretory 27 
and sympathetic response. 28 
 29 
RESULTS 30 
 6 
Intimate dendro-somatic and dendro-dendritic interrelationships between 1 
presympathetic and magnocellular neurosecretory PVN neurons.  2 
It is well-documented that neurosecretory and presympathetic neuronal somata in 3 
the PVN are anatomically compartmentalized within specific subnuclei (Swanson and 4 
Kuypers, 1980; Swanson and Sawchenko, 1980). Using a combination of retrograde 5 
tract tracing and immunohistochemistry to identify presympathetic PVN neurons that 6 
innervate the rostroventrolateral medulla (RVLM; PVN-RVLM neurons) and VP MNNs, 7 
respectively, we verified this early observation (Fig.1A). However, a more detailed 8 
analysis revealed that thick and varicose dendritic processes from VP MNNs extended 9 
beyond their own neuronal compartment, coming in close proximity to somatodendritic 10 
elements of presympathetic neurons in the ventromedial, dorsal cap and posterior 11 
parvocellular subnuclei (Swanson and Kuypers, 1980) (Fig.1B-G). The identity of these 12 
processes as dendrites was confirmed by MAP2 immunoreactivity (Fig.1I), and by being 13 
abutted by numerous dopamine  hydroxylase (DBH)-immunoreactive presynaptic 14 
boutons (Fig.1J). Conversely, VP axons ran laterally out of the PVN boundaries, then 15 
turning ventrally and caudally towards the median eminence (Fig.1H) (Swanson and 16 
Kuypers, 1980). These studies support thus a distinctive anatomical microenvironment 17 
that would enable dendro-dendritic/somatic communication from neurosecretory to 18 
presympathetic neurons, possibly via dendritically released VP. 19 
Activation of V1a receptors in presympathetic PVN neurons increases their firing 20 
activity via a Ca2+-dependent activation of TRPM4/5 channels.  21 
To determine if presympathetic neurons sense dendritically-released VP from 22 
MNNs, we first assessed for the expression of V1a receptors (the most common type of 23 
VP receptor found in the brain (Zingg, 1996)) in retrogradely-labeled PVN-RVLM 24 
neurons. As shown in Fig.2A-D, we found a dense V1a receptor immunoreactivity in 25 
somato-dendritic regions of presympathetic neurons.  Similar results were found with an 26 
alternative V1a antibody (Fig.S1), recently shown to label V1a receptors in olfactory 27 
bulb neurons (Tobin et al., 2010). The resolution of the light microscopic approach 28 
however, does not readily distinguish V1a clusters located near the surface membrane 29 
of PVN-RVLM neurons from ones potentially located at presynaptic terminals.  Further 30 
 7 
supporting the expression of V1a receptors by PVN-RVLM neurons, however, we report 1 
expression of V1a receptor mRNA in these neuronal population (Fig.2E). 2 
Focal application of VP onto presympathetic PVN neurons resulted in direct 3 
membrane depolarization and increased firing discharge (n=16, P<0.001, Fig.2F-I). VP 4 
effects were almost completely blocked by # 4'-'%5+7' !# 3'%'1503 #/5#)0/+45 H-5 
Mercapto-HH-cyclopentamethylenepropionyl1, O-me-Tyr2, Arg8]-Vasopressin, 1 µM, P< 6 
0.01, n=8, Fig.2H), but persisted in the presence of the ionotropic glutamate and 7 
GABAA receptor antagonists kynurenate (1 mM) and bicucculine (20 µM)(basal: 0.30 8 
± 0.13 Hz; VP: 2.75 ± 0.53 Hz, P<0.01, n=6), or in the presence of a low Ca2+ synaptic 9 
block media (basal: 0.58 ± 0.38 Hz; VP: 3.85 ± 0.38 Hz, P< 0.02).  10 
The VP-mediated increase in firing activity in presympathetic neurons was preceded 11 
(3.1 ± 0.8 s) by an increase in [Ca2+]I (P< 0.01, n=8, Fig.3A-C), and was abolished by 12 
chelation of intracellular Ca2+ with BAPTA (10 mM) (n=8, Fig.3D). In voltage-clamp 13 
mode, VP evoked an outwardly rectifying current with an apparent reversal potential of   14 
~ -15 mV (Fig.3E). Taken together, these results support the involvement of a Ca2+-15 
activated non-selective cation current (CAN) (Petersen, 2002). We found PVN-RVLM 16 
neurons to express dense immunoreactivity (Fig.S2A-D) and mRNA (Fig.S2E) for 17 
TRPM4 channels, a major CAN channel member of the transient receptor potential 18 
(TRP) family (Ullrich et al., 2005), and previously reported in the hypothalamus 19 
(Ghamari-Langroudi and Bourque, 2002; Teruyama and Armstrong, 2007; Teruyama et 20 
al., 2011). We also found that VP excitatory effects on PVN-RVLM neurons were 21 
blocked by flufenamic acid (FFA, 200 µM) (n=9, Fig.S2F), a relatively specific blocker of 22 
TRPM4/5 channels (Ullrich et al., 2005). In the presence of FFA, PVN-RVLM neurons 23 
were still capable of displaying a burst of action potential in response to a puff of 20 µM 24 
NMDA (n=3, not shown), indicating that FFA effects were not due to non-specific effects 25 
on overall neuronal function, or due to changes in PVN-RVLM responsiveness to 26 
NMDA. Further studies however, are needed to precisely identify the molecular identity 27 
of the CAN channel underlying VP actions in presympathetic neurons.   28 
Dendritic release of vasopressin mediates cell-cell communication between 29 
neighboring neurosecretory and presympathtic neurons.  30 
 8 
To directly probe for a crosstalk between MNNs and presympathetic neurons, we 1 
developed an approach using transgenic eGFP-VP rats (Ueta et al., 2005) that received 2 
an injection of a fluorescent retrograde tracer in the RVLM (Fig.S3). Our approach 3 
consisted on selectively activating individual VP neurons using laser photolysis of 4 
caged-NMDA, while simultaneously monitoring the electrical activity of neighboring 5 
presympathetic neurons in acute hypothalamic slices. To validate this approach, we 6 
show that laser photolysis of caged-NMDA onto restricted somatodendritic regions of 7 
patched eGFP-VP neurosecretory neurons induced reproducible inward currents along 8 
with a concurrent high-frequency burst of action potentials (Fig.4A), previously shown to 9 
efficiently evoke dendritic release of peptides from MNNs in brain slices (Kombian et al., 10 
1997). Moreover, photolysis of caged-NMDA in the somata of Fluo-5F loaded eGFP-VP 11 
neurons increased [Ca2+]i levels, which rapidly propagated into dendritic compartments 12 
(Fig.S4).  13 
To test the hypothesis that dendritic VP release acts as a crosstalk signal between 14 
neurosecretory and presympathetic neurons, we then obtained patch recordings from  15 
PVN-RVLM neurons, and assessed their responses to photolysis of caged-NMDA in 16 
neighboring eGFP-VP neurons. On average, 3 different eGFP-VP neurons were 17 
photoactivated per patched PVN-RVLM neuron. The mean distance between the 18 
somata of presympathetic and the photoactivated VP neurons was 111.6±7.9 µm.  19 
Photolysis of caged-NMDA at the somata of individual eGFP-VP neurons consistently 20 
evoked an excitatory response in neighboring PVN-RVLM neurons, characterized by a 21 
burst of activity, which was underlain by a membrane depolarization (n=38 eGFP-VP 22 
neurons/11 PVN-RVLM neurons, P< 0.001, Fig.4B). Responses in presympathetic 23 
neurons occurred with a mean latency of 3.5 ± 1.0 sec following photolysis in 24 
neighboring eGFP-VP neurons. In a few cases (n=4), stimulation of an eGFP-VP 25 
neuron failed to evoke a response in PVN-RVLM neurons, which were however 26 
responsive to other eGFP-VP neurons in the same preparation. 27 
Direct photolysis of caged-NMDA onto the recorded neurons (eGFP-VP or 28 
presympathetic) resulted in an almost instantaneous effect (P< 0.05 n=11, Fig.4). 29 
Importantly, presympathetic responses to photoactivation of eGFP-VP neurons were 30 
almost completely blocked following bath application of the V1a receptor antagonist 31 
 9 
Fig.4C). No relationship between the uncaging distance and magnitude or delay of the 1 
evoked response was observed.  2 
While action potentials are necessary for axonal VP release, dendritic release can 3 
occur in Ca2+-dependent, but action potential-independent manner (Ludwig et al., 2002). 4 
Thus, to rule out a potential, but unlikely contribution of VP released from an axon 5 
collateral within the PVN (Hatton et al., 1985; Ludwig, 1998), experiments were 6 
repeated in the presence of 1 µM TTX. Under these conditions, photolysis of NMDA 7 
onto eGFP-VP neurons still evoked a membrane depolarization in neighboring PVN-8 
RVLM neurons (n=18), effects that were blocked by the V1a receptor antagonist (P< 9 
0.01, n=14, Fig.5). Conversely, following activation of eGFP-VP neurons, 10 
presympathetic responses were prevented by a 0 Ca2+ / 3 mM EGTA aCSF (1.2 ± 0.2 11 
mV, n=10, P> 0.3), without altering PVN-RVLM responses to direct uncaging of NMDA 12 
(5.5 ± 0.5 mV, P< 0.05 n=4). These results support that Ca2+-dependent dendritic 13 
release of VP (Ludwig et al., 2002) stimulates the activity of neighboring presympathetic 14 
PVN neurons via activation of V1a receptors. 15 
To rule out the possibility that PVN-RVLM neuronal responses were due to diffusion 16 
of caged-NMDA beyond the photoactivated region in the eGFP-VP neurons, a subset of 17 
recorded PVN-RVLM neurons were dialysed with the NMDAR blocker MK-801 (1 mM). 18 
While intracellular MK801 significantly blocked the effect of direct photolysis of caged-19 
NMDA onto the recorded neurons (1.3 ± 0.9 mV, P> 0.2, n=4), photolysis onto eGFP-20 
VP neurons still evoked a depolarizing response from the same PVN-RVLM neurons 21 
(5.2 ± 1.4 mV, P< 0.05, n=4) (Fig.S5). Additional controls included laser stimulation 22 
without the presence of caged-NMDA, and bath application of caged-NMDA alone, both 23 
of which failed to evoke neuronal responses (not shown). Finally, NMDA uncaging onto 24 
eGFP-VP neurons (n=33) failed to evoke changes in [Ca2+]I in the vast majority of    25 
Rhod-2 loaded astrocytes (~87%). In the few responsive astrocytes, increases in  [Ca2+]I 26 
occurred with a long delay (> 40 s) (Fig.S6). 27 
To further prove the neurosecretory-presympathetic neuronal crosstalk, we 28 
performed dual-patch recordings from identified eGFP-VP and PVN-RVLM neurons. In 29 
13/15 pairs tested, we found that evoked bursting firing in VP neurons resulted in a 30 
significant membrane depolarization (P< 0.001, n=13) and increase firing discharge (P< 31 
 10 
0.02, n=13) in the neighboring presympathetic neurons (Fig.6B,F). These effects were 1 
largely blocked following bath application of the V1a antagonist (n=7) or in pairs in 2 
which eGFP-VP neurons were dialyzed with BAPTA (n=5) (Fig.6C,F). No responses 3 
were observed in the remaining two pairs. We found that the latency for the evoked 4 
PVN-RVLM depolarization was significantly longer when a prominent after-5 
hyperpolarizing potential (AHP) following the evoked bursts of action potentials was 6 
observed in the paired eGFP-VP neuron (n=9, Fig.6B1), compared to neurons in which 7 
AHPs were absent (n=6, Fig.6B2), or those in which a depolarizing afterpotential (DAP) 8 
was observed instead (n=3; Fig.6D) (P<0.001, Fig.6E). Moreover, a significant 9 
correlation between the eGFP-VP AHP duration and the PVN-RVLM latency was found  10 
(Pearson r= 0.89, P< 0.0001). The mean latency in paired recordings in which AHPs in 11 
eGFP-VP neurons were absent was similar to that observed following photolysis of 12 
caged NMDA (P> 0.3, see above), in which AHPs were not observed. In contrast to the 13 
effect on latency, the magnitude of the PVN-RVLM response was independent of the 14 
presence or duration of an AHP in the stimulated eGFP-VP neurons (not shown).  15 
Finally, to determine whether astrocytes participate as intermediaries in the 16 
neurosecretory-presympathetic crosstalk, experiments were repeated following 17 
functional ablation of astrocytes with the selective gliotoxin L-aminoadipic acid (L-AAA, 18 
250 µM, 30-60 min)(McBean, 1994; Xu et al., 2008). Under this condition, stimulation of 19 
eGFP-VP neurons still efficiently evoked an excitatory response in PVN-RVLM neurons 20 
(P< 0.001, n=5, (Fig.6D,F). 21 
 In a few cases (n=4) in which both neurons where intracellularly labeled with 22 
fluorescent dyes, segments of dendrites from the paired neurons were found in close 23 
proximity (12.5 ± 3.1 µm) (Fig.6G1-G3).  24 
An activity-dependent diffusible VP pool tonically stimulates presympathetic 25 
neuronal activity. 26 
Our results demonstrate that evoked dendritic peptide release from an individual VP 27 
neuron can diffuse locally to affect the activity of a neighboring presympathetic neuron. 28 
We then tested whether the basal average activity of the neurosecretory VP population 29 
as a whole was sufficient to generate a tonic diffusing peptide pool, to continuously 30 
modulate presympathetic neuronal activity. Blockade of V1a receptors per se resulted in 31 
 11 
membrane hyperpolarization and inhibition of firing activity in presympathetic neurons 1 
(P< 0.001 and P< 0.01, respectively, n=14, Fig.7A,B), unveiling the presence of a 2 
diffusible, tonic pool of VP. Conversely, the firing activity of eGFP-VP neurons was not 3 
affected (baseline: 2.2 ± 0.6 Hz; V1a antagonist: 2.2 ± 0.7 Hz, n=5). To test whether the 4 
strength of the diffusible pool was dependent on the degree of activity of the VP 5 
population, we performed manipulations that either increased or decreased VP neuronal 6 
activity. The VP tone was enhanced by increasing extracellular K+ concentration (8.0 7 
mM K+), as indicated by a more pronounced effect of the V1a antagonist in this 8 
condition, compared to normal K+ ACSF (P< 0.01, Fig. 7D). Conversely, in the presence 9 
of the  opiod receptor agonist U-50488 (1 µM), known to strongly inhibit VP neuronal 10 
activity (P< 0.01, Fig.S7A, see also (Brown et al., 1998)), the V1a antagonist effect on 11 
presympatehtic neuronal activity was significantly blunted (P< 0.05 vs. control, 12 
Fig.7C,D). In the presence of the V1a antagonist, however, U-50488 failed to affect the 13 
firing activity of presympathetic neurons (P> 0.6, n=4, Fig.S7B), arguing against a direct 14 
effect of U50488 on the latter. No correlation between basal PVN-RVLM firing activity 15 
and the magnitude of the V1a antagonist effect was found in any of these different 16 
conditions (Pearson r value: -0.02, P> 0.5). Dialysis of BAPTA into the recorded PVN-17 
RVLM neurons prevented the effects of the V1a antagonist (baseline: 0.7 ± 0.1 Hz; V1a 18 
antagonist: 0.6 ± 0.1 Hz, P>0.3, n=6).  19 
A diffusible signal in the ECS could be influenced both by its half-life and the ECS 20 
tortuosity. Blockade of tissue aminopeptidase activity (amastatin 10 µM), increased the 21 
firing activity of presympathetic neurons (P< 0.01, n=8, Fig.7E). The amastatin effect 22 
was not only blocked, but actually turned into an inhibitory effect in the presence of the 23 
V1a receptor blocker (P< 0.01 vs. amastatin control, n=7, Fig.7E). These results 24 
indicate that aminopeptidase blockade increased not only the availability and excitatory 25 
actions of endogenous VP, but also of an unknown inhibitory signal, which was only 26 
unmasked when the VP excitatory effect was blocked. The identity of this inhibitory 27 
peptide signal was not further investigated in this study. 28 
Reducing the coefficient of diffusion in the ECS with 5% dextran (40 kDA) (Min et al., 29 
1998; Piet et al., 2004) also blocked the V1a antagonist effect on presympathetic firing 30 
discharge (-6.5 ± 8.8%, P> 0.6, n=4). Taken together, these results indicate that 31 
 12 
tonically released VP within the PVN serves as a neurosecretory population signal, 1 
which acting in a diffusible manner, increased the activity of the presympathetic PVN 2 
neuronal population. 3 
 4 
Dendritic release of VP within the PVN contributes to the recruitment of 5 
sympathetic neurons during an osmotic challenge. 6 
We finally assessed whether dendritic release of VP serves as an inter-population 7 
signal by which the integrated sympathoexcitatory output from the entire presympathetic 8 
neuronal population was modulated. To this end, we performed in vivo studies to 9 
directly monitor sympathoexcitatory outflow from the PVN. We found that direct 10 
microinjection of VP (8-32 pmol) onto the PVN elicited a dose-dependent 11 
sympathoexcitatory response, reflected by an increase in renal sympathetic nerve 12 
activity (RSNA, P< 0.02, n=9, Fig.8A,B). These results indicate that the VP excitatory 13 
effect observed on presympathetic neurons in vitro translated into a systemic, 14 
population sympathoexcitatory response.  15 
It is well-documented that a central osmotic challenge results in a robust PVN 16 
homeostatic response that involves an orchestrated activation of VP MNNs and 17 
presympathetic neurons, leading to increased plasma VP levels along with a 18 
concomitant increase in sympathetic outflow (Bourque, 2008; Toney and Stocker, 19 
2010), respectively. Thus, we used this paradigm to assess the functional relevance of 20 
the neurosecretory-presympathetic crosstalk in the context of a homeostatic challenge. 21 
Intra-carotid infusions of graded concentrations of NaCl (0.3, 0.9 and 2.1 osmol/l) 22 
induced a significant and dose-dependent increase in RSNA (P<0.0001, n=7, 23 
Fig.8C,D). This osmotically-driven sympathoexcitatory response was significantly 24 
attenuated (~50%) by a previous bilateral microinjection of the V1a antagonist within the 25 
PVN (2 nmol in 100 nl, P< 0.001 vs. control, Fig.8C,D). As shown in Fig.8E, the 26 
intracarotid osmotic stimulation evoked a significant increase in VP release within the 27 
SON (P< 0.001, one way ANOVA repeated measures, n=7). These results indicate that 28 
osmotically-driven dendritic VP release participates in the recruitment of presympathetic 29 
neurons during a homeostatic challenge requiring an orchestrated neurosecretory and 30 
sympathetic response. 31 
 13 
 1 
DISCUSSION 2 
The two modalities by which the PVN commands the generation of complex 3 
homeostatic responses are represented in distinct neuronal populations, including 4 
neurosecretory neurons projecting to the median eminence or the posterior pituitary, 5 
and presympathetic neurons innervating the spinal cord and/or brainstem nuclei, 6 
including the rostroventrolateral medulla (RVLM) (Swanson and Sawchenko, 1980). 7 
Given its diverse, though well-characterized anatomical and functional organization, the 8 
PVN stands as an ideal brain region to study inter-population signaling modalities in the 9 
brain. Despite its highly integrative function, it is well-documented that neurosecretory 10 
and presympathetic PVN neuronal populations are anatomically compartmentalized, 11 
displaying minimal or complete lack of hard-wired interconnections (Hatton et al., 1985; 12 
Swanson and Kuypers, 1980; Swanson et al., 1980). This has led to the notion that 13 
polymodal homeostatic control by the PVN involves parallel processing of 14 
neuroendocrine and autonomic information. In this study, we challenged this prevailing 15 
idea by testing the novel hypothesis that dendritic release of peptides serves as an 16 
inter-population signal mediating crosstalk between neurosecretory and presympathetic 17 
PVN neuronal populations. Along with nigrostriatal dopaminergic neurons (Cheramy et 18 
al., 1981), hypothalamic MNNs are one the best-characterized prototypes of dendritic 19 
neurotransmitter release (Ludwig and Leng, 2006). Dendritic release of VP and OT from 20 
MNNs acts as powerful feedback signals by which MNNs auto-regulate their own 21 
activity, to optimize systemic hormone release in response to physiologically relevant 22 
challenges (Kombian et al., 1997; Ludwig and Leng, 1997). Results from the present 23 
study demonstrate that in addition to its autocrine actions, VP acts as a diffusible signal 24 
to bridge information across neurosecretory and presympathetic neuronal populations. 25 
This novel crosstalk involves Ca2+-dependent dendritic release of VP, diffusion in the 26 
extracellular space, and activation of V1a VP receptors coupled to a CAN channel in 27 
presympathetic neurons. Lastly, we demonstrate this crosstalk modality to be critical for 28 
an optimal homeostatic sympathetic response to a central osmotic challenge (Bourque, 29 
2008; Toney and Stocker, 2010).  30 
 31 
 14 
Dendritically released VP mediates a neurosecretory-to-presympathetic neuronal 1 
crosstalk.  2 
We found that selective activation of a single neurosecretory VP neuron (either by 3 
photolytic NMDA uncaging or direct current injection in dual-patch recordings) evoked a 4 
V1a receptor-mediated depolarization and firing discharge in neighboring 5 
presympathetic (PVN-RVLM) neurons. Several lines of evidence support that the 6 
underlying mechanism involved activation of a Ca2+-activated non-selective cation 7 
(CAN) channel (Petersen, 2002), including: (a) VP induced in PVN-RVLM neurons an 8 
increase in [Ca2+]I that preceded the enhanced membrane excitability; (b) intracellular 9 
Ca2+ dependency of the VP effect, (c) voltage-dependent properties of IVP, including an 10 
outwardly rectifying I/V curve and (d) the IVP reversal potential, characteristic of a mixed-11 
cationic conductance. While our pharmacological (flufenamic acid), 12 
immunohistochemical and single-cell RTPCR experiments (Fig.S2) suggest the 13 
involvement of TRPM4 channels, recently reported to be present in MNNs (Teruyama et 14 
al., 2011), future studies are needed to identify the precise molecular identity of the 15 
underlying CAN channel.  16 
Following bursts of action potentials, VP neurons express two types of opposing 17 
post-spike membrane potentials: AHPs and DAPs. These potentials temporally overlap, 18 
competing with each other to either inhibit or increase post-firing membrane excitability, 19 
respectively (Armstrong et al., 2010). We found that when prominent AHPs were 20 
observed in the stimulated VP neurons, the response latency of the presympathetic 21 
/'630/4 8#4 130-0/)'& *+4 46))'454 5*#5 4 #%5 #4 # ?$3#,+/)@ 4:45'. 5*#522 
efficiently regulate activity-dependent dendritic VP release, and consequently, the timing 23 
of the inter-neuronal crosstalk in the PVN. 24 
MNNs project almost exclusively to the posterior pituitary (Swanson and Kuypers, 25 
1980), with only a few reported cases of scarce axon collaterals, arising from, but 26 
terminating outside the PVN (Hatton et al., 1985). Thus, the topographical segregation 27 
between the dendritic and axonal terminal fields of MNNs minimized the possibility that 28 
photolytically-evoked VP released within the PVN originated from an axon terminal, 29 
rather than a dendritic source. This is further supported by our results showing that the 30 
evoked neurosecretory-presympathetic crosstalk persisted in the presence of TTX, 31 
 15 
which prevents axonal but not somatodendritic release of neuropeptides from MNNs. 1 
Similar to dorsal raphe serotonin neurons (de Kock et al., 2006), NMDA was shown to 2 
evoke dendritic release from MNNs in the absence of action potentials (de Kock et al., 3 
2004), and dendritic VP release involves a Ca2+-dependent exocytotic event (Ludwig et 4 
al., 2002). Accordingly, we found that photolysis of caged-NMDA in the somata of VP 5 
neurons resulted in a rise in [Ca2+]i both in neuronal somata and dendrites. This in turn 6 
was followed by an excitatory response in presympathetic neurons, which was 7 
prevented by a synaptic block media. Finally, intracellular Ca2+ chelation in VP neurons 8 
prevented the neurosecretory-presympathetic coupling observed in dual-patch 9 
recordings.  10 
While the combined anatomical, imaging and electrophysiological data reported here 11 
strongly support a direct communication between neurosecretory and presympathetic 12 
neurons, we cannot conclusively rule out the participation of other intermediaries. For 13 
example, the evoked VP release from a single MNN could act in a recurrent positive 14 
feedback manner to recruit additional VP neurons to release further amounts of VP 15 
(Kombian et al., 1997; Ludwig and Leng, 1997). Moreover, dendritically released VP 16 
could also act on nearby astrocytes to evoke release of a potential gliotransmitters. 17 
However, our data showing that stimulation of VP neurons failed to consistently activate 18 
nearby astrocytes, and the fact that the neurosecretory-presympathetic coupling 19 
persisted following ablation of astrocyte function, would argue against this possibility.   20 
 21 
Dendritically released VP acts as a diffusible inter-population signal contributing 22 
to homeostatic neurohumoral responses 23 
Given its long half-life (~20 min in the brain (Mens et al., 1983)), VP is ideally suited 24 
to act as a diffusible signal, potentially affecting multiple neurons at relatively distant 25 
locations. We found the firing activity of presympathetic PVN neurons to be tonically 26 
45+.6-#5'& $: #/ '/&0)'/064 ! ?50/'@ whose strength was enhanced either by 27 
increasing the activity of VP neurons, or by prolonging VP lifetime in the extracellular 28 
space (aminopeptidase block) (Chen and Pittman, 1999). Conversely, the strength of 29 
the VP tone was diminished when VP neuronal activity was inhibited ( opiod 30 
agonist)(Brown et al., 1998), or when the coefficient of diffusion of molecules in the ECS 31 
 16 
was lessened (5% dextran) (Piet et al., 2004).  Thus, our findings support the ability of 1 
dendritically released VP from the neurosecretory population to act in a diffusible 2 
manner to modulate the activity of neighboring presympathetic neurons.  3 
 A central hyperosmotic challenge triggers a coordinated systemic release of VP, 4 
along with an increased renal sympathetic nerve activity (RSNA) (Bourque, 2008; Toney 5 
and Stocker, 2010). These responses are largely mediated by activation of 6 
neurosecretory and presympathetic SON/PVN neuronal populations, respectively 7 
(Antunes et al., 2006; Chen and Toney, 2001; Leng et al., 2001; Oliet and Bourque, 8 
1993). In addition to systemic release, osmotic stimuli also evoke local dendritic release 9 
of VP (Leng and Ludwig, 2008) 8*+%* 4'37'4 #4 # ?1016-#5+0/ (''&$#%,@ 4+)/#- $:10 
which VP neurons auto-regulate their own activity to optimize hormone secretion from 11 
their axonal terminals (Gouzenes et al., 1998). In this study, we found that a 12 
hyperosmotic-induced increase in RSNA was largely attenuated when V1a receptors 13 
within the PVN were locally blocked.  14 
Given that VP MNNs are intrinsically osmosensitive (Oliet and Bourque, 1993), it is 15 
reasonable to speculate that osmotically-driven dendritic VP release effectively 16 
augmented the endogenous neurosecretory VP tone, directly stimulating in turn the 17 
neighboring presympathetic neuronal population. Alternatively, dendritically released VP 18 
could also act by increasing presympathetic neuronal responsiveness to forebrain 19 
glutamatergic afferent inputs, known to contribute to osmotically-driven sympathetic 20 
responses by the PVN (Antunes et al., 2006; Shi et al., 2007). This could occur either by 21 
strengthening osmosensitive glutamatergic afferents (i.e., pre- or post-synaptically), or 22 
simply by depolarizing the presympathetic resting membrane potential closer to spike 23 
threshold. We found that VP excitatory effects on presympathetic PVN neurons 24 
persisted in the presence of ionotropic glutamate receptor blockade, suggesting that a 25 
direct VP excitatory signal per se is sufficiently strong to evoke firing discharge and 26 
increase sympathetic outflow from the presympathetic neuronal population.  27 
The extent to which other PVN neuronal populations are also targeted by 28 
dendritically released VP is at present unknown. Clearly, recruitment specificity is a 29 
critical factor for the generation of a physiologically relevant homeostatic responses, 30 
 17 
which is likely achieved by the selective expression of V1a receptors in the relevant 1 
neuronal populations.  2 
Collectively, our findings provide, to the best of our knowledge, the first 3 
demonstration that activity-dependent dendritic release of peptides constitutes an 4 
efficient inter-population signaling modality in the brain. More specifically, they support 5 
our hypothesis that a local crosstalk between hypothalamic neurosecretory and 6 
presympathetic neuronal populations plays an important role in the generation of central 7 
integrative homeostatic responses (Pittman et al., 1982). Finally, given that 8 
neurohumoral activation (a process involving elevated neurosecretory and sympathetic 9 
outflows) is a hallmark in prevalent diseases such as hypertension and heart failure 10 
(Cohn et al., 1984; Esler et al., 1995; Pliquett et al., 2004), our studies provide insights 11 
into potentially novel pathophysiological mechanism contributing to morbidity and 12 
mortality in these prevalent diseases.  13 
 14 
EXPERIMENTAL PROCEDURES 15 
 16 
Animals. Male Wistar rats (160-220 g) were purchased from Harlan laboratories 17 
(Indianapolis, IN), and housed in a 12 hr:12 hr light-dark cycle with access to food and 18 
water ad libitum.  In a subset of experiments, we also used male heterozygous 19 
transgenic VP-eGFP Wistar rats (5-6 weeks old), in which VP neurons are 20 
endogenously fluorescent (Ueta et al., 2005). All procedures were carried out in 21 
agreement with the University of Georgia Health Sciences and the University of 22 
Nebraska Medical Center Institutional Animal Care and Use Committee guidelines, and 23 
were approved by the respective committees. 24 
Retrograde tracing. To identify presympathetic RVLM-projecting PVN neurons (PVN-25 
RVLM), rats were anesthetized (ketamine-xylazine mixture, 90 and 50 mg kg-1, 26 
respectively, i.p.) and a stereotaxic apparatus was used to pressure inject 500 nl of 27 
rhodamine-labeled microspheres (Lumaflor, Naples, FL, USA) or cholera toxin B (CTB) 28 
(1%, List Biological Laboratories) into the RVLM (starting from Bregma: 12 mm caudal 29 
along the lamina, 2 mm medial lateral, and 8 mm ventral). Injection sites were contained 30 
within the caudal pole of the facial nucleus to ~ 1 mm more caudal, and were ventrally 31 
 18 
located with respect to the nucleus ambiguous. The location of the tracer was verified 1 
histologically (Sonner et al., 2011). Injections located either more rostral or lateral to the 2 
targeted area did not result in PVN labeling, and these animals were discarded from the 3 
study. Animals were used 3-4 days after surgery.  4 
Slice preparation. Rats were anesthetized with pentobarbital (50 mg kg-1) and 5 
perfused through the heart with a cold sucrose solution (containing in mM: 200 sucrose, 6 
2.5 KCl, 3 MgSO4, 26 NaHCO3, 1.25 NaH2PO4, 20 D-glucose, 0.4 ascorbic acid, 1 7 
CaCl2 and 2 pyruvic acid (290-310 mosmol l-1).  Rats were decapitated, brains dissected 8 
065#/&%030/#-4-+%'4	I.0(5*'*:105*#-#.64%0/5#+/+/)5*'!8'3'%65+/#/9 
oxygenated ice cold ACSF (containing in mM: 119 NaCl, 2.5 KCl, 1 MgSO4, 26 10 
NaHCO3, 1.25 NaH2PO4, 20 D-glucose, 0.4 ascorbic acid, 2 CaCl2 and 2 pyruvic acid; 11 
pH 7.4; 290-310 mosmol l-1), using a vibroslicer (D.S.K. Microslicer, Ted Pella, Redding, 12 
CA). For synaptic blockade, a 0.2 mM CaCl2 and 400 µM CdCl2 ACSF was used. In 13 
other cases, a 0 mM CaCl2 / 3 mM EGTA solution was used, as indicated. Slices were 14 
kept in a holding chamber containing ACSF (room temperature) until used.  15 
Electrophysiology.  Hypothalamic slices were transferred to a recording chamber and 16 
superfused with ACSF (30>32 °C) at a flow rate of ~3.0 ml minB1. Conventional whole-17 
cell patch clamp recordings were obtained as previously described (Sonner et al., 18 
2011). Patch pipettes (4-G%0.104'&0(5*+/8#--'&..065'3&+#meter, 1.17 19 
mm inner diameter) borosilicate glass (GC150T-7.5, Clark, Reading, UK), were pulled 20 
on a horizontal electrode puller (P-97, Sutter Instruments, Novato, CA).  The internal 21 
solution contained (mM): 135 potassium gluconate, 10 EGTA, 10 HEPES, 10 KCl, 0.9 22 
MgATP, 0.3 NaGTP and 20 phosphocreatine (Na+); pH 7.2-7.3.  When noted, neurons 23 
were intracellularly labeled with Alexa Fluor 555 (100 µM) or biocytin (1%). Recordings 24 
were obtained with a Multiclamp 700A amplifier (Axon Instruments, Foster City, Ca) 25 
from fluorescently-labeled PVN-RVLM neurons located in the parvocellular ventromedial 26 
or dorsal cap subnuclei, or from eGFP-VP neurons, located in the lateral magnocellular 27 
subnucleus. Neurons were visualized with a combination of fluorescence illumination 28 
and infrared differential interference contrast (IR-DIC) videomicroscopy. The voltage-29 
output was digitized at 16-bit resolution, 10 kHz (Digidata 1320A, Axon Instruments), 30 
 19 
and saved on a computer for offline analysis. For current-clamp recordings, all protocols 1 
were run using an output gain of 5 and a Bessel filter of 2 kHz. Firing activity and 2 
membrane potential were recorded in continuous mode before and during application of 3 
drugs. For bath-applied drugs, mean values were calculated from a 2-min period before 4 
drug application, and in a 2-min period around the peak effect.  For briefer applications 5 
(picospritzer) and uncaging, values were calculated from a 1-mi period before, and 10-6 
20 sec period around the peak effect, using Clampfit (Axon Instruments, Foster City, 7 
Ca) or miniAnalysis (Synaptosoft Inc., NJ) software. DC current injection was used in an 8 
attempt to maintain neurons at a similar low level of basal firing activity, while holding 9 
them at an approximate membrane potential of -45 to -55 mV. The mean series 10 
resistance was monitored throughout the recording (< 20 M) and data discarded if 11 
changes >20% were observed).  12 
Confocal calcium imaging. Magnocellular neurosecretory neurons were loaded 13 
through the patch pipette with Fluo-5F pentapotassium 4#-5I0-'%6-#330$'414 
Carlsbad, CA), as previously described(Filosa et al., 2006; Sonner et al., 2011). Once in 15 
the whole-cell mode, the dye was allowed to dialyze into the cell for at least 20 minutes 16 
before the initiation of the recordings, in order to allow complete dialysis of the dye. For 17 
astrocyte Ca2+ measurements, slices were incubated at room temperature (RT) in ACSF 18 
containing Rhod2-#/&1-630/+%#%+&	I).- .#)+/)8#4%0/&6%5'&64+/) 5*' 19 
Yokogawa real time live cell laser confocal system combined with a highly-sensitive 20 
EMCCD camera (iXON+885, Andor Technology, South Windsor, CT).  Fluorescence 21 
images were obtained using diode-pumped solid-state laser (Melles Griot, Carlsbad, 22 
CA) at 488 nm and emitted light at >495 (Fluo4) or 561 nm and emitted light >607 nm 23 
(Rhod2). Images were acquired at a rate of 4 Hz. The fractional fluorescence (F/F0) was 24 
determined by dividing the fluorescence intensity (F) within a region of interest (ROI; 6 x 25 
6 pixels   9  I. by a baseline fluorescence value (F0) determined from 30 26 
images before photolysis of caged-NMDA. Data was analyzed using Andor IQ software 27 
(Andor Technology). 28 
 29 
Photolysis of caged-compounds. Uncaging was performed using the Andor 30 
Technology Revolution system (iXON EMCCD camera with the Yokogawa CSU 10, 31 
 20 
confocal scanning unit). Slices were perfused with MNI-caged-NMDA (50 IM). A UV 1 
laser excitation (405 nm) was directed to a region of interest drawn on the image of 2 
identified PVN-RVLM or eGFP-VP somata through a 40x or 63x microscope objective. 3 
Based on the pixel dwell time (200-800 µs) and the ROI area scanned (~ 40 µm2), the 4 
uncaging protocol lasted 180 > 720 ms. The confocality of the system allows for the 5 
photolysis beam to occur at the focal plane of choice, with minimal diffusion beyond the 6 
activated plane. Uncaging was done while simultaneously recording neuronal firing 7 
activity or F"Ca2+]I in the slice (see Figs.S4-S5). For these experiments, an ACSF 8 
containing 20 µM Mg2+ was used to facilitate detection of evoked NMDA responses, 9 
although similar but smaller responses were also observed in control ACSF (not 10 
shown). 11 
PVN microinjections and in vivo renal sympathetic nerve activity (RSNA) 12 
measurements.  On the day of the experiment, rats were anesthetized with urethane 13 
),) +1 #/& D-chloralose (70mg/kg i.p.) and the left femoral artery was 14 
cannulated and connected to a computer-driven data recording and analyzing system 15 
(PowerLab, ADI instruments, Colorado springs, CO, USA) via a pressure transducer 16 
(Gould P23 1D) for recording arterial blood pressure and heart rate. The anesthetized 17 
rat was placed in a stereotaxic apparatus (Davis Kopf Instruments, Tujunga, CA, USA). 18 
A longitudinal incision was made on the head and the bregma was exposed. The 19 
coordinates for the PVN were determined from the Paxinos and Watson Atlas. They 20 
were 1.5mm posterior to the bregma, 0.4mm lateral to the midline, and 7.8mm ventral to 21 
the dura. A small burr hole was made in the skull. For the microinjections, a thin needle 22 
(0.5mm OD and 0.1mm ID) connected to a micro syringe (0.5ml; model 7000.5 23 
Hamilton micro syringe) was lowered into the PVN. To record RSNA, the left kidney was 24 
exposed through a retroperitoneal flank incision. A branch of the renal nerve was 25 
isolated from the fat and connective tissue and was placed on a pair of thin bipolar 26 
platinum electrodes. The nerve-electrode junction was insulated electrically from the 27 
surrounding tissue with a silicone gel (Wacker Sil-Gel, 604 A B). The electrical signal 28 
was amplified (10000 times) with a Grass amplifier (P55) with a high- and low-frequency 29 
cutoff of 1000 and 100Hz, respectively. The output signal from the Grass amplifier was 30 
directed to a computer-run data acquisition system (PowerLab, ADI instruments, 31 
 21 
Colorado springs, CO, USA) to record and integrate the raw nerve discharge. The 1 
signal recorded at the end of the experiment (after the rat was dead) was deemed as 2 
background noise. The basal value of the nerve activity was defined by subtracting the 3 
background noise from the actual nerve activity value before the administration of drugs 4 
into the PVN. The peak response of RSNA to the administration of drugs into the PVN 5 
during the experiment (averaged over a period of 20-30s) was subsequently expressed 6 
as a percent change from baseline (Biancardi et al., 2011).  7 
 8 
Central hyperosmotic stimulation and VP microdialysis. Central hyperosmotic 9 
stimulation was achieved by delivering graded concentrations of NaCl (0.3, 0.9, and 2.1 10 
osmol/l) through an internal carotid artery (ICA) catheter. The ICA is the main artery 11 
supplying limbic areas, including the hypothalamus, and this approach was previously 12 
shown to elicit efficiently and reproducibly central, but not peripheral hyperosmolarity 13 
(Chen and Toney, 2001). Injections were delivered in a volume of 300 µl over a period 14 
of 10-15 seconds. For microdialysis, rats were anaesthetized with urethane (ethyl 15 
carbamate, intraperitoneally 1.2 g/kg, Sigma Chemical Co., UK). In-house designed 16 
microdialysis probes (molecular weight cut-off of 6 kDa, Fleaker® Hollow Fibre, 17 
Spectrum® Med. Inc., USA) were stereotaxically implanted with the U-shaped tip 18 
located within or adjacent to the right SON (1.0 mm posterior to bregma; 1.7 mm lateral 19 
to midline; 9.3 mm below the surface of the skull, as previously described (Ludwig et al., 20 
2002). After an equilibration period of at least 1 h, consecutive 30-min dialysis samples 21 
were collected at a flow rate of 3 l/min. After two 30-min baseline periods, rats were 22 
stimulated osmotically as described above, and a further two consecutive dialysate 23 
samples were collected, frozen and stored at -20oC until assay for vasopressin. The 24 
vasopressin content in the microdialysates was measured by a highly sensitive and 25 
selective radioimmunoassay (detection limit: 0.1 pg/sample; cross-reactivity less than 26 
0.7%) as previously described (Landgraf et al., 1995). 27 
 28 
Immunohistochemistry. Rats were anesthetized with pentobarbital (50 mg kg-1) and 29 
perfused transcardially in 4% paraformaldehyde in 0.01 M phosphate buffer saline 30 
(PBS).  Brains were then removed, postfixed for 2-4 hours, cryoprotected in 30% 31 
 22 
sucrose in 0.01 M PBS (4 °C, 3 days), and then stored at -80 °C until further use. 1 
030/#- 4-+%'4 
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Slices were then incubated in 0.01 M PBS with 0.1% Triton X-100, 0.04% NaN3 3 
(PBSTXNaN3), and 5% normal horse serum for 1 hour at room temperature.  Slices were 4 
then rinsed thoroughly with 0.01 M PBS, followed by incubation with one or a 5 
combination of the following primary antibodies rabbit (1:100; Millipore) or goat (1:50; 6 
Santa Cruz) anti-V1a receptor; goat anti-CTB (1:2500; List Biological Laboratories); 7 
rabbit anti-TRPM4 (1:2000, kindly donated by Dr. Teruyama, LHSU, Baton Rouge); 8 
rabbit anti-microtubule-associated protein 2 (MAP2, 1:500, Sigma); Mouse anti-9 
dopamine  hydroxylase (DBH, 1:20,000, Millipore). Incubation in primary antibodies 10 
(overnight at 4 °C in PBSTXNaN3) where followed by specific fluorescently labeled 11 
secondary antibodies (1:250; Jackson ImmunoResearch Laboratories, West Grove, 12 
Pennsylvania, USA) for 4 hours at 4 °C in PBSTXNaN3.  Slices were then rinsed 13 
thoroughly, mounted, and visualized using confocal microscopy (Carl Zeiss 14 
MicroImaging, Inc., Thornwood, NY, USA; 63x oil immersion, zoomed x2; single optical 15 
1-#/'I.5*+%,(Biancardi et al., 2010).   Negative controls included incubations in 16 
the absence of primary antibodies and preabsorption with the respective antigen 17 
peptide, as previously done (Biancardi et al., 2010). Both of these control approaches 18 
resulted in absence of staining (see for example Fig.S1). 19 
 20 
Single cell RTPCR. Single cell RT-PCR was carried out as previously described with 21 
minor modification (Sonner et al., 2011). The cytoplasm of the patched neuron, taking 22 
care not to contain the nucleus, was pulled into a patch pipette containing 2 µl DEPC-23 
treated water, and then mixed with 1 µl of RNase inhibitor (Applied Biosystems, Foster 24 
city, CA, USA) and immediately frozen in liquid nitrogen, and kept at -80 C until 25 
processed. RT for cDNA was carried out with iScript cDNA Synthesis Kit (BIO-RAD, CA, 26 
  #%%03&+/) 50 .#/6(#%563'3A4 .#/6#-  #.1-+(+%#5+0/ 8#4 performed with a 27 
fraction of cDNA as a template. The mixture of PCR reaction containe& +/ I-  0(28 
I'#%*13+.'30(	C.#45'3.+9$6(('30#23''/#45'3+930.')#29 
and 8 of the cDNA template. The annealing temperature in the thermal cycler was 60 °C 30 
and 50 cycles were performed. A nested approach was used to quantify V1a receptor 31 
 23 
mRNA. The primers used included: First nested PCR: 5E-cgaggtgaacaatggcactaaaac-3E 1 
and 5E-tgtgatggaagggttttctgaatc-3E; Second nested PCR 5E-tcatctgctaccacatctggcg-3E and 2 
5E-gtgtaaccaaaagccccttatgaaag-3E; Primers for TRPM4: 5E-cctgcaggcccaggtagaga-3E and 3 
5E-ttcagcagagcgtccatgag-3E  13+.'34 A-ttcaacggcacagtcaagg-
A #/& A-4 
tggttcacacccatcacaaa-
A--13+.'348'3'4:/5*'4+;'&$:/5'3)3#5'&5'%*/0-0)+'45 
(Iowa, USA). Final PCR products were electrophoresed on a 2% agarose gels in TAE 6 
buffer (40mM Tris-#%'5#5'.1%0/5#+/+/)I).-'5*+&+6.$30.+&'7 
observed UV light, and photographed. Negative controls were performed by replacing 8 
cDNA with water.  9 
Statistical Analysis. All values are expressed as means ± S.E.M. In most cases, 10 
unpaired or paired t tests were used, as indicated.  One or two-way ANOVA tests with 11 
0/('330/+1045*0%5'4548'3'64'&#4/''&'&'#340/A4%033'-#5+0/5'458#464'&5012 
determine if correlations existed between two parameters.  Differences were considered 13 
significant at P< 0.05.  All statistical analyses were conducted using GraphPad Prism 14 
(GraphPad Software, San Diego, CA). 15 
 16 
Drugs.  All drugs with the exception of MNI-caged-NMDA (Tocris, Ellisville, MO USA), 17 
were purchased from Sigma-Aldrich (St. Louis, MO, USA).  For simplicity, the selective 18 
!# #/5#)0/+45 H-Mercapto-HH-cyclopentamethylenepropionyl1, O-me-Tyr2, Arg8]-19 
Vasopressin +).# !		 +4 3'('33'& 50 #4 ?!# #/5#)0/+45@ 5*306)*065 5*'20 
manuscript.  21 
22 
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FIGURE LEGENDS 1 
 2 
Figure 1. Dendro-somatic and dendro-dendritic interrelationships between 3 
presympathetic and magnocellular neurosecretory PVN neurons.  (A) Confocal 4 
image showing the topographical segregation between immunoreactive magnocellular 5 
neurosecretory vasopressin (VP, green) and retrogradely-labeled presympathetic PVN-6 
RVLM (red) neuronal somata. In (B) and (C), the squared regions are shown at 7 
progressively higher magnification, to better depict the presence of thick and varicose 8 
VP dendrites within the presympathetic neuronal compartment. Additional examples of 9 
VP dendrites extending from the lateral magnocellular subnucleus into the three main 10 
presympathetic PVN subnuclei, including the dorsal cap (D), parvocellular ventromedial  11 
(E) and parvocelluar posterior (F) are shown. (G) PVN-RVLM neurons surrounded by 12 
VP dendrites are shown at high magnification. (H) Low magnification image of the PVN 13 
showing that the vast majority of immunoreactive vasopressin (green) and oxytocin 14 
(red) axons emerge from the PVN, running laterally and ventrally towards the median 15 
eminence. (I) Image showing thick, immunoreactive VP processes (green), which are 16 
also MAP2 immunoreactive (white, arrows) nearby a PVN-RVLM neuron (red, asterisk). 17 
Note the abundance of MAP2 processes that are negative for VP. (J) Image showing 18 
DBH immunoreactive boutons (white, arrows) abutting VP-immunoreactive processes 19 
(green) near a PVN-RVLM neuron (red, asterisk). Vertical and horizontal arrows point 20 
dorsally and ventrally, respectively. 3V: third ventricle. Scale bars in A-G= 20 µm; H= 21 
200 µm; I, J= 5 µm.  22 
 23 
Figure 2. Presympathetic PVN neurons express functional V1a receptors. (A) 24 
Sample confocal image at low magnification showing CTB-retrogradely-labeled PVN-25 
RVLM neurons (blue), and V1a receptor immunoreactivity (green, Millipore primary 26 
antibody) in the PVN. In (B) and (C), examples of two PVN-RVLM neurons showing 27 
dense V1a immunoreactive clusters, respectively, are depicted. In (D), the squared area 28 
in (B) is shown at an expanded scale, to better show V1a immunoreactive clusters 29 
(arrows) located at the surface of the shown dendrite. (E) Single-cell V1a mRNA 30 
expression in identified PVN-RVLM and eGFP-VP neurons. A non-template negative 31 
 25 
control is shown in the right lane, and a small piece of a DNA ladder is shown in the left 1 
lane. (F) A puff of VP (1 µM, arrowheads) delivered directly onto a presympathetic PVN-2 
RVLM neuron evokes a high-frequency burst of action potentials. (G) Sample trace 3 
showing that in the presence of tetrodotoxin (TTX 0.5 µM), puffs of VP of decremental 4 
durations depolarized a presympathetic PVN neuron in a proportionally decremental 5 
manner. Note the presence of Ca2+ spikes (arrow). (H) Summary data of VP effects on 6 
firing activity and (I) membrane potential in presympathetic neurons (n=16). Scale bars 7 
in A, B= 20 µm; D= 2.5 µm. 8 
 9 
Figure 3. VP effects on presympathetic neurons involves an increase in [Ca2+]I 10 
and activation of a CAN channel. (A), Sample traces showing simultaneous [Ca2+]I 11 
(lower) and membrane potential (upper) measurements in a PVN-RVLM neuron in 12 
response to bath-applied VP (1 µM, line). Note that the increase in [Ca2+]I preceded 13 
the increase in firing discharge. (B), Representative pseudocolor (upper) and black and 14 
white (lower) images of VP-evoked Ca2+ changes in the PVN-RVLM neuron shown in A. 15 
Image numbers correspond to the time points shown in A. (C), Summary data showing 16 
mean VP-evoked Ca2+ changes (F/F0) in presympathetic PVN neurons (n=8). (D), 17 
Sample trace and summary data showing that chelation of intracellular Ca2+ with 18 
BAPTA (10 mM) in the patch pipette prevented VP excitatory effect (puff, arrowhead) in 19 
presympathetic PVN neurons (n=8). (E) Sample trace in voltage-clamp mode showing a 20 
VP-mediated (puff, arrowhead) inward current (IVP) in a presympathetic PVN neuron. 21 
The right panel shows a mean I/V plot of IVP evoked at various holding potentials (n=5). 22 
**P< 0.01.  23 
 24 
Figure 4. Photo-activation of neurosecretory VP neurons evokes a V1a receptor-25 
mediated excitatory response in neighboring presympathetic neurons. (A1) 26 
Inward currents evoked in a patched eGFP-VP neuron following photolysis of caged-27 
NMDA onto various somatodendritic regions of interest (ROI) (1-3). Note that photolysis 28 
in an ROI a few microns away from the recorded neuron (4) failed to evoke a response. 29 
(A2), Repetitive laser photolysis of caged NMDA onto the same eGFP-VP neuron 30 
evoked reproducible inward currents (upper trace), membrane depolarizations (lower 31 
 26 
trace), and bursts of action potentials (right traces). (B1) Slice containing a patched 1 
presympathetic PVN-RVLM neuron (red, asterisk) and neighboring eGFP-VP neurons  2 
(green, 1-4) that were activated with photolysis of caged-NMDA. (B2) Direct uncaging of 3 
NMDA onto the patched presympathetic neuron (asterisk, yellow flashes) evoked a 4 
burst of action potentials. (B3) Burst of action potentials recorded in the patched 5 
presympathetic neuron in response to uncaging of NMDA onto the eGFP-VP neurons 6 
shown in B1 (1-4, red flashes). Note the delayed response in the PVN-RVLM neurons 7 
compared to B2. (C1) Combined DIC and fluorescence image of a slice containing a 8 
patched presympathetic neuron (asterisk) and neighboring eGFP-VP neurons  (green). 9 
(C2) Presympathetic neuronal responses to uncaging of NMDA onto the recorded PVN-10 
RVLM neuron neuron (upper traces) or onto an eGFP-VP neuron (arrow in C1, and 11 
lower traces), in control ACSF (left) and in the presence of a V1a receptor antagonist 12 
(right). (C3) Summary data of mean changes in the number of action potentials, action 13 
potential frequency, and membrane potential in presympathetic PVN-RVLM neurons, 14 
evoked by photolysis of caged-NMDA onto the presympathetic neurons themselves 15 
(n=11, left) or onto eGFP-VP neurons in the absence (n=38, middle) or presence (n=7, 16 
right) of the V1a antagonist. *P< 0.01 and **P< 0.001 vs. respective ACSF.  17 
 18 
Figure 5. The NMDA-mediated crosstalk between neurosecretory VP and 19 
presympathetic PVN-RVLM neurons is not dependent on action potential firing. 20 
(A1) Sample of a slice containing a patched presympathetic PVN-RVLM neuron that 21 
was loaded with alexa fluor 555 (red, asterisk) and neighboring eGFP-VP neurons 22 
(green) that were photoactivated with caged-NMDA. (A2) Representative traces 23 
obtained from the recorded PVN-RVLM neuron following 5 repetitive photolysis of 24 
caged-NMDA directly onto the recorded cell (upper trace, yellow flashes), or in 25 
response to simultaneous photolysis onto the three eGFP-VP neurons (1-3, red flashes) 26 
shown in A1, in control ACSF + 1 µM TTX (middle trace), and following bath application 27 
of the V1a receptor antagonist + TTX (lower trace). (B) Summary data of mean changes 28 
in PVN-RVLM membrane potential evoked in the presence of TTX following photolysis 29 
of caged-NMDA onto the presympathetic neurons themselves (n=6, blue bar), or onto 30 
eGFP-VP neurons (red bars) in the absence (n=18, middle bar) or presence (n=14, right 31 
 27 
bar) of the V1a receptor antagonist. (C1) Another example showing a recorded 1 
presympathetic PVN-RVLM neuron (alexa fluor 555, red) and a photoactivated eGFP-2 
VP neuron (green, arrow). (C2) Sample traces obtained from the PVN-RVLM neuron 3 
from C1, following photolysis of caged-NMDA in the presence of 1 µM TTX directly onto 4 
the PVN-RVLM neuron itself (asterisk, upper trace, yellow flash), or onto an eGFP-VP 5 
neuron (red flashes), in control ACSF (middle trace) and following bath application of 6 
the V1a receptor antagonist (lower trace), in the presence of TTX. *P< 0.01 vs. 7 
respective ACSF. Scale bars: 15 µm. 8 
 9 
Figure 6. Neurosecretory-presympathetic crosstalk unveiled during dual-patch 10 
recordings from eGFP-VP and PVN-RVLM neurons. (A1) Sample pair of 11 
intracellularly labeled (Alexa 633, blue, arrows) PVN neurons during simultaneous dual-12 
patch recordings. The identity of the patched neurons as eGFP-VP (cyan, single arrow) 13 
and retrogradely-labeled PVN-RVLM (purple, double arrow) is shown in A2. (B1) 14 
Electrically evoked bursting activity in the eGFP-VP neuron resulted in a delayed 15 
membrane depolarization and increased firing discharge in the neighboring PVN-RVLM 16 
neuron. Note the pronounced AHP following action potential firing in the eGFP-VP 17 
neuron (filled arrowhead). (B2) Another sample of paired recordings showing a similar 18 
response. Note however the lack of AHP in the eGFP-VP neuron (empty arrowhead), 19 
and the shorter latency of the evoked PVN-RVLM response. (C) Sample of a paired 20 
recording in which the eGFP-VP neuron was dialysed with BAPTA. Note the lack of 21 
response in the PVN-RVLM neuron. (D) Sample of a paired recording in the presence of 22 
L-aminoadipic acid (L-AAA, 250 µM, 30 min), showing an increase in PVN-RVLM firing 23 
activity following stimulation of the eGFP-VP neuron. Note the presence of a DAP in the 24 
eGFP-VP neuron (double filled arrowheads), and the brief latency for the evoked PVN-25 
RVLM response. (E) Comparison of the mean inter-neuronal coupling latency in eGFP-26 
VP neurons displaying or not an AHP following the evoked burst of action potentials 27 
(n=10 and 8, respectively). (F) Summary data of mean changes in PVN-RVLM 28 
membrane potential (left) and firing activity (right) following direct stimulation of eGFP-29 
VP neurons in control ACSF (n=13), V1a antagonist (n=7), intracellular BAPTA in the 30 
stimulated eGFP-VP neuron (n=5) and in the presence of L-AAA (n=5). G1-G3, Another 31 
 28 
representative example of dual-patched and intracellularly-labeled eGFP and PVN-1 
RVLM neurons. (G1), Single focal plane of a confocal image showing eGFP-VP (green) 2 
and PVN-RVLM (red) neurons. The recorded PVN-RVLM neuron was intracellularly 3 
filled with Alexa 633 (arrow, colocalization= purple), and the recorded eGFP-VP neuron 4 
was intracellularly filled with Alexa 555 (arrowhead, colocalization= yellow). In G2, the 5 
same image as in A1, but a confocal stack of 10 images is shown to better depict the 6 
dendritic processes of the recorded neurons. The blue color has been transformed to 7 
white for better clarity. Asterisk points to a dendritic end of the eGFP-VP (Alexa 555 8 
filled) neuron. In G3, the squared area in G2 is shown at a magnified scale. **P< 0.001 9 
vs. AHP; +P< 0.05 and #P< 0.01 vs. V1a antagonist and BAPTA, respectively.  Scale 10 
bars: A, B= 25 µm; G1, G2= 20 µm; G3= 10 µm.  Action potentials were cropped.  11 
 12 
Figure 7. An activity-dependent diffusible pool of dendritically-released VP 13 
tonically modulates presympathetic neuronal activity. (A) Sample trace showing a 14 
hyperpolarization and diminished firing discharge of a presympathetic neuron following 15 
bath application of the V1a receptor blocker (1 µM). At the arrow, DC current injection 16 
was applied to bring the membrane potential back to control levels, to show that the V1a 17 
antagonist efficiently blocked the neuronal response to a VP puff (1 µM, arrowhead). (B) 18 
Summary data of the effects of the V1a receptor antagonist on firing frequency and 19 
membrane potential of presympathetic neurons (n=14). (C) Sample trace showing a 20 
blunted effect of the V1a receptor antagonist in the presence of the  receptor agonist 21 
U-50488 (1 µM). (D) Summary data of the effects of the V1a antagonist on 22 
presympathetc neuronal firing in control ACSF (K+ 2.5 mM), high K+ ACSF (8.5 mM) and 23 
in U-50488 (K+ 2.5 mM) (n= 6, 7 and 8, respectively). (E) Sample traces and summary 24 
data showing the effects of the aminopeptidase blocker amastatin (10 µM, 10 min) in 25 
control ACSF and in the presence of the V1a receptor antagonist (n=8 in each group). 26 
*P< 0.05; **P< 0.01 and ***P< 0.001. 27 
 28 
Figure 8. Dendritic release of VP within the PVN contributes to 29 
sympathoexcitatory homeostatic responses following a central hyperosmotic 30 
challenge. (A) Representative traces showing changes in raw (lower) and integrated 31 
 29 
(upper) renal sympathetic nerve activity (RSNA) following administration of VP (16 1 
pmol) onto the PVN. (B) Summary data showing dose-dependent increases in RSNA 2 
after microinjections of VP (8, 16 and 32 pmol) onto the PVN (P< 0.02, one way 3 
ANOVA, n=9). (C) Representative traces showing changes in RSNA following intra-4 
carotid infusions of an isosmotic (NaCl 0.3 osmol/l) or hyperosmotic (NaCl 2.1 osmol/l) 5 
solution, following bilateral microinjections of ACSF or of the V1a receptor antagonist ((2 6 
nmol/100 nl, 6-10 mins before the osmotic challenge) onto the PVN. Note the increase 7 
in RSNA evoked by the hyperosmotic challenge in control ACSF (arrow) but not in the 8 
presence of the V1a receptor antagonist. (D) Summary data showing dose-dependent 9 
increases in RSNA after intra-carotid infusions of NaCl (0.3, 0.9 and 2.1 osmol/l) in 10 
animals that received an intra-PVN microinjection of either ACSF or the V1a receptor 11 
antagonist (*P< 0.0001 vs. respective ACSF, n=7). (E) Summary data showing 12 
increased VP content in 30-min microdialysates sampled from the SON before and after 13 
an intracarotid infusion of NaCl 2.1 osmol/l (arrow) (*P< 0.05 vs. basal levels, n=7). 14 
15 
 30 
SUPPLEMENTARY FIGURE LEGENDS 1 
Figure S1. V1a receptor immunoreactivity in presympathetic PVN neurons.  2 
Sample confocal images showing V1a receptor immunoreactivity (A1, B1, C1, green 3 
Santa Cruz primary antibody) and retrogradely-labeled PVN-RVLM neurons (A2, B2, 4 
C2, red, asterisks). In A3, B3, and C3, images were superimposed. Arrows point to V1a 5 
immunoreactive clusters at the surface of the PVN-RVLM neurons.  The insets in A3 6 
and B3 show a portion of the PVN-RVLM neurons (rectangles) at expanded scales. 7 
Within the insets, arrows and arrowheads point to V1a cluster possibly located near the 8 
neuronal surface membrane and/or at presynaptic terminals, respectively. Images in C 9 
were obtained from tissue in which the antibody was preabsorbed with the 10 
corresponding antigen (5-fold molar excess relative to IgG concentration).  Scale bars: 11 
A3-C3: 10 µm; inset in B3: 2.5 µm.  12 
 13 
Figure S2. Expression of functional TRPM4 channels in presympathetic PVN 14 
neurons. (A) Sample confocal image at low magnification showing TRPM4 (green), and 15 
retrogradely-labeled PVN-RVLM neurons (red). The asterisk indicates the center of the 16 
lateral magnocellular subnucleus. (B, C, D) Three different samples at higher 17 
magnification showing TRMP4 immunoreactive  (left, green) PVN-RVLM neurons (right, 18 
red). (E) Single-cell TRMP4 mRNA expression in identified PVN-RVLM neurons. A non-19 
template negative is shown in the right lane, and a small piece of a DNA ladder is 20 
shown in the left lane. (F) Sample traces showing VP effects (puff, arrowheads) on a 21 
presympathetic PVN neuronal firing activity before (left) and after (right) bath application 22 
of flufenamic acid (FFA, 200 µM), a relative selective blocker of TRPM4/5 channels. The 23 
right graph shows the summary data (n=9). ***P< 0.001. Scale bars in A= 50 µm; B, C, 24 
D= 10 µm. 3V= third ventricle. 25 
 26 
Figure S3. Identification of presympathetic and neurosecretory VP neurons using 27 
retrograde tract tracing in eGFP-AVP transgenic rats. (A) Sample confocal image of 28 
a PVN slice showing large eGFP-VP neurons (green) in the lateral magnocellular 29 
subnucleus (LM), along with smaller retrogradely-labeled PVN-RVLM neurons (red) in 30 
the dorsal cap (DC) and parvocellular ventromedial (PaV) subnculei. The inset shows 31 
 31 
dense eGFP staining in the posterior pituitary (PP) of an eGFP-VP rat. (B) Confocal 1 
micrograph showing high degree of colocalization (yellow) between eGFP (green) and 2 
vasopressin (red) immunoreactivity in the PVN. (C) Confocal micrograph showing lack 3 
of colocalization between eGFP (green) and oxytocin (red) immunoreactivity in the PVN. 4 
Scale bars: (A)= 40 µm; inset: 400 µm (B) and (C)= 15 µm. 3V: third ventricle. Vertical 5 
and horizontal arrows point dorsally and medially, respectively. 6 
 7 
Figure S4. Changes in somatodendritc [Ca2+]i levels in eGFP-VP neurons in 8 
response to  laser photolysis of caged-NMDA. (A) Sample showing that photolysis of 9 
caged-NMDA onto the soma of a patched eGFP-VP neuron evoked a rapid and 10 
transient change in dendritic [Ca2+]i (red arrows). Image 1 is a projection image of the 11 
recorded neuron through a Z stack (40 µm). Single confocal planes before, during, and 12 
after (4 s) photolysis of caged-NMDA are shown in images 2-4, respectively. (B) Plots of 13 
changes in dendritic [Ca2+]i (F/F0) as a function of time (obtained from the ROI show in 14 
A1), following NMDA uncaging in the soma of the eGFP-VP neuron using increasing 15 
laser pixel dwelling times. Traces were purposely shifted in the X-axis for their better 16 
comparison. (C) Summary data showing that changes in dendritic [Ca2+]i following 17 
somatic uncaging of NMDA was dependent on the laser pixel dwelling time (F= 4.3, P< 18 
0.01, 1 way ANOVA, n=6). *P< 0.05 vs. 100 and 200 µs dwell times). Scale bar in A = 19 
15 µm. 20 
 21 
Figure S5. Blockade of NMDA receptors in presympathetic PVN-RVLM neurons 22 
does not prevent the excitatory effect mediated by photolysis of caged-NMDA 23 
onto eGFP-VP neurons. (A) Sample of a combined DIC and fluorescence image of a 24 
slice containing a patched presympathetic PVN-RVLM neuron that was dialysed with 25 
the NMDA receptor blocker MK801 (1 mM, asterisk), and a neighboring eGFP-VP 26 
neuron  (green, 1). (B) Lack of response to direct photolysis of caged-NMDA onto the 27 
patched PVN-RVLM neuron (upper trace, yellow flash). The middle and lower traces 28 
show the response of the same PVN-RVLM neuron to photolysis of caged-NMDA onto 29 
the eGFP-VP neuron (1, red flashes) in control ACSF and following bath application of 30 
the V1a receptor antagonist, respectively.  31 
 32 
 1 
Figure S6. Photolysis of caged-NMDA onto eGFP-VP neurons failed to evoke 2 
increases in intracellular Ca2+ in the majority of nearby astrocytes. (A) Sample of 3 
Rhod-2 labeled astrocytes (red, 1-5) in the vicinity of an eGPF-VP neuron (green, 4 
arrow) photoactivated with caged-NMDA. (B) Traces showing Ca2+ levels (F/F0) in the 5 
respective astrocytes shown in A1, following NMDA uncaging onto the eGFP-VP neuron 6 
(arrow and vertical line). Note the delay increase in Ca2+ (asterisks) in astrocytes 1-3. 7 
(C) Summary data showing the total number of negative and positive responding 8 
astrocytes following NMDA uncaging onto 33 different eGFP-VP neurons. Scale bar in 9 
A1= 15 µm.  10 
 11 
Figure S7. Activation of  opioid receptors robustly inhibits firing discharge in 12 
identified eGFP-VP neurons. (A) Sample trace showing a robust membrane 13 
hyperpolarization and inhibition of firing activity of an eGFP-VP neuron evoked by bath 14 
application of the  receptor agonist U-50488 (1 µM). The summary data (n= 5) is 15 
shown in (B). (C) Sample trace obtained from a presympathetic PVN-RVLM neuron in 16 
the presence of the V1a receptor antagonist, showing lack of effect of U-50488 (1 µM) 17 
on firing activity. The summary data (n= 4) is shown in (D). **P< 0.01.   18 
 19 
20 
 33 
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